Refine
Has Fulltext
- yes (45)
Is part of the Bibliography
- yes (45)
Year of publication
- 2020 (45) (remove)
Document Type
- Journal article (44)
- Doctoral Thesis (1)
Language
- English (45) (remove)
Keywords
- multiple myeloma (9)
- relapse (4)
- B cells (3)
- refractory (3)
- 18F-FDG PET/CT (2)
- cancer (2)
- inflammation (2)
- management (2)
- mortality (2)
- 11C-Methionine PET/CT (1)
- 3D culture (1)
- 68Ga-Pentixafor PET/CT (1)
- AKT-signaling (1)
- ALiOS (1)
- ASE formula (1)
- Adaptive cell transfer (1)
- Aspergillus fumigatus (1)
- Aspergillus sp. (1)
- Autologous hematopoietic stem cell transplantation (1)
- B cell (1)
- CAR T cell (1)
- CAR T cells (1)
- CCL3 (1)
- CCL4 (1)
- CCL5 (1)
- CCS (1)
- CD38 (1)
- CMV reactivation (1)
- COX2 expression (1)
- Candida sp. (1)
- Coronavirus Disease 2019 (1)
- Donor lymphocytes (1)
- EGFR (1)
- HB-EGF (1)
- HGF (1)
- HNSCC (1)
- Hämostase (1)
- Infectious complications (1)
- JCV (1)
- KRAS (1)
- MAPKAPK2 (1)
- MEK/ERK-signaling (1)
- MOR202 (1)
- MYC (1)
- Megakaryozyt (1)
- Met (1)
- Myeloma (1)
- NAFLD (1)
- NASH (1)
- NGS (1)
- NLRP3 (1)
- NRF2 (1)
- PD-L1 (1)
- PML (1)
- POU6F2-AS2 (1)
- Pom‐PAD‐Dara (1)
- Prodigy (1)
- Radiochemotherapy (1)
- Rectal cancer (1)
- Rhizopus arrhizus (1)
- Severe Acute Respiratory Syndrome Coronavirus 2 (1)
- Surgery (1)
- Systemic sclerosis (1)
- T cell (1)
- T cells (1)
- TLR agonists (1)
- TNFSF14 (1)
- TNFSF4 (1)
- TSLP (1)
- Tdp-43 (1)
- Teichholz formula (1)
- Time interval (1)
- VCE (1)
- Western diet (1)
- Zink (1)
- acute lymphoblastic leukaemia (1)
- acute respiratory distress syndrome (1)
- adalimumab (1)
- adverse events (1)
- amplicon sequencing (1)
- amyotrophic lateral sclerosis (1)
- anticoagulation (1)
- antithrombotic therapy (1)
- anxiety (1)
- atrial fibrillation (1)
- autoimmune encephalitis (1)
- autoimmunity (1)
- autologous stem cell transplantation (1)
- axonal transcriptome (1)
- binding (1)
- blinatumomab (1)
- bone (1)
- bone marrow angiogenesis (1)
- bridging (1)
- cancer vaccines (1)
- capture (1)
- carfilzomib (1)
- cfRNA (1)
- chimeric antigen receptor (1)
- clinical trial (1)
- colonoscopy (1)
- common variable immunodeficiency (1)
- complications (1)
- corticosteroids (1)
- cytokines (1)
- daratumumab (1)
- ddPCR (1)
- definition (1)
- dendritic cells (1)
- discharge definition (1)
- donor-cell leukemia (1)
- drug screening (1)
- early detection (1)
- echocardiography (1)
- endothelial cells (1)
- extramedullary disease (1)
- fluorescence (1)
- fungal aerosolization (1)
- fungal infection (1)
- fungal infections (1)
- galactomannan (1)
- gene (1)
- genetic susceptibility (1)
- growth differentiation factor 15 (1)
- head and neck cancer (1)
- helicase (1)
- hematologic malignancies (1)
- hematological malignancies (1)
- hemodialysis (1)
- immune response (1)
- immune therapy (1)
- immunity (1)
- immuno-oncology (1)
- immunotherapeutics (1)
- immunotherapy (1)
- incidence (1)
- inflammasome (1)
- inflammation-induced tissue demage (1)
- interacts (1)
- interleukin 1 (1)
- interleukin 18 (1)
- invasive aspergillosis (1)
- kinease (1)
- left ventricular hypertrophy (1)
- left ventricular mass index (1)
- lenalidomide (1)
- lentiviral transduction (1)
- life-threatening side-effects (1)
- liquid biopsy (1)
- low molecular heparin (1)
- lymphocytes (1)
- mantle cell lymphoma (1)
- mechanosensing (1)
- mechanotransduction (1)
- melanoma malignancy (1)
- memory B cells (1)
- metabolic tumor volume (MTV) (1)
- methionine (1)
- molecular diagnosis (1)
- monocytes (1)
- multiplex PCR (1)
- muscle (1)
- music (1)
- myokines (1)
- nOAC (1)
- natural killer cell (1)
- newly diagnosed (1)
- nicotinamide (1)
- novel therapies (1)
- nuclear receptors (1)
- nucleotide excision repair (1)
- obinutuzumab (1)
- oral anticoagulants (1)
- organoids (1)
- osteokines adaptation (1)
- pancreatectomy (1)
- pathophysiology (1)
- pattern (1)
- personalised medicine (1)
- porcine large animal model (1)
- postoperative bleeding (1)
- pre-clinical models (1)
- primary immunodeficiencies (1)
- progression (1)
- prostaglandin E2 (1)
- pulmonary immune response (1)
- radiogenomics (1)
- recognition (1)
- relaxation (1)
- rheumatoid arhritis (1)
- safety (1)
- serum biomarkers (1)
- small bowel bleeding (1)
- smoldering myeloma (1)
- stem cell transplantation (1)
- stress level (1)
- subunit (1)
- sulfur (1)
- superior (1)
- surgical care (1)
- t-lymphocytes (1)
- thromboembolism (1)
- tocilizumab (IL-6 inhibitor) (1)
- total lesion glycolysis (TLG) (1)
- total lesion methionine uptake (TLMU) (1)
- toxicity (1)
- transactivation (1)
- tumor microenvironment (1)
- tumor-infiltrating (1)
- tumor-specific CD8+ T cells (1)
- tumor‐specific antigen (1)
- venetoclax (1)
- video capsule endoscopy (1)
- warfarin interruption (1)
Institute
- Medizinische Klinik und Poliklinik II (45) (remove)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 733297 (2)
- 19-COP-0031 (1)
- 641458 (1)
- 754658 (1)
- 847507 (1)
- 853988 (1)
- EU-1650-0006 (1)
In the last few years, monoclonal antibodies (mAbs) such as elotuzumab and daratutumab have brought the treatment of multiple myeloma (MM) into the new era of immunotherapy. More recently, chimeric antigen receptor (CAR) modified T cell, a novel cellular immunotherapy, has been developed for treatment of relapsed/refractory (RR) MM, and early phase clinical trials have shown promising efficacy of CAR T cell therapy. Many patients with end stage RRMM regard CAR T cell therapy as their “last chance” and a “hope of cure”. However, severe adverse events (AEs) and even toxic death related to CAR T cell therapy have been observed. The management of AEs related to CAR T cell therapy represents a new challenge, as the pathophysiology is not fully understood and there is still no well-established standard of management. With regard to CAR T cell associated toxicities in MM, in this review, we will provide an overview of experience from clinical trials, pathophysiology, and management strategies.
Protein inclusions containing the RNA-binding protein TDP-43 are a pathological hallmark of amyotrophic lateral sclerosis and other neurodegenerative disorders. The loss of TDP-43 function that is associated with these inclusions affects post-transcriptional processing of RNAs in multiple ways including pre-mRNA splicing, nucleocytoplasmic transport, modulation of mRNA stability and translation. In contrast, less is known about the role of TDP-43 in axonal RNA metabolism in motoneurons. Here we show that depletion of Tdp-43 in primary motoneurons affects axon growth. This defect is accompanied by subcellular transcriptome alterations in the axonal and somatodendritic compartment. The axonal localization of transcripts encoding components of the cytoskeleton, the translational machinery and transcripts involved in mitochondrial energy metabolism were particularly affected by loss of Tdp-43. Accordingly, we observed reduced protein synthesis and disturbed mitochondrial functions in axons of Tdp-43-depleted motoneurons. Treatment with nicotinamide rescued the axon growth defect associated with loss of Tdp-43. These results show that Tdp-43 depletion in motoneurons affects several pathways integral to axon health indicating that loss of TDP-43 function could thus make a major contribution to axonal pathomechanisms in ALS.
Background and Aims: Colonoscopy as standard procedure in endoscopy is often perceived as uncomfortable for patients. Patient's anxiety is therefore a significant issue, which often lead to avoidance of participation of relevant examinations as CRC-screening. Non-pharmacological anxiety management interventions such as music might contribute to relaxation in the phase prior and during endoscopy. Although music's anxiolytic effects have been reported previously, no objective measurement of stress level reduction has been reported yet. Focus of this study was to evaluate the objective measurement of the state of relaxation in patients undergoing colonoscopy.
Methods: Prospective study (n = 196) performed at one endoscopic high-volume center. Standard colonoscopy was performed in control group. Interventional group received additionally self-chosen music over earphones. Facial Electromyography (fEMG) activity was obtained. Clinician Satisfaction with Sedation Instrument (CSSI) and Patients Satisfaction with Sedation Instrument (PSSI) was answered by colonoscopists and patients, respectively. Overall satisfaction with music accompanied colonoscopy was obtained if applicable.
Results: Mean difference measured by fEMG via musculus zygomaticus major indicated a significantly lower stress level in the music group [7.700(±5.560) μV vs. 4.820(±3.330) μV; p = 0.001]. Clinician satisfaction was significantly higher with patients listening to music [82.69(±15.04) vs. 87.3(±15.02) pts.; p = 0.001]. Patient's satisfaction was higher but did not differ significantly.
Conclusions: We conclude that self-chosen music contributes objectively to a reduced stress level for patients and therefore subjectively perceived satisfaction for endoscopists. Therefore, music should be considered as a non-pharmacological treatment method of distress reduction especially in the beginning of endoscopic procedures.
The transcription factor NRF2 is the major mediator of oxidative stress responses and is closely connected to therapy resistance in tumors harboring activating mutations in the NRF2 pathway. In melanoma, such mutations are rare, and it is unclear to what extent melanomas rely on NRF2. Here we show that NRF2 suppresses the activity of the melanocyte lineage marker MITF in melanoma, thereby reducing the expression of pigmentation markers. Intriguingly, we furthermore identified NRF2 as key regulator of immune-modulating genes, linking oxidative stress with the induction of cyclooxygenase 2 (COX2) in an ATF4-dependent manner. COX2 is critical for the secretion of prostaglandin E2 and was strongly induced by H\(_2\)O\(_2\) or TNFα only in presence of NRF2. Induction of MITF and depletion of COX2 and PGE2 were also observed in NRF2-deleted melanoma cells in vivo. Furthermore, genes corresponding to the innate immune response such as RSAD2 and IFIH1 were strongly elevated in absence of NRF2 and coincided with immune evasion parameters in human melanoma datasets. Even in vitro, NRF2 activation or prostaglandin E2 supplementation blunted the induction of the innate immune response in melanoma cells. Transcriptome analyses from lung adenocarcinomas indicate that the observed link between NRF2 and the innate immune response is not restricted to melanoma.
This study aimed to explore the correlation between imaging patterns and clinical features in patients with smoldering multiple myeloma (SMM) who simultaneously underwent 18F-FDG, 11C-Methionine, and 68Ga-Pentixafor positron emission tomography/computed tomography (PET/CT). We retrieved and analyzed clinical characteristics and PET imaging data of 10 patients with SMM. We found a significant correlation between bone marrow (BM) plasma cell (PC) infiltration and mean standardized uptake values (SUV\(_{mean}\)) of lumbar vertebrae L2-L4 on 11C-Methionine PET/CT scans (r = 0.676, p = 0.031) and 68Ga-Pentixafor PET/CT scans (r = 0.839, p = 0.002). However, there was no significant correlation between BM involvement and SUV\(_{mean}\) of lumbar vertebrae L2-L4 on 18F-FDG PET/CT scans (r = 0.558, p = 0.093). Similarly, mean target-to-background ratios (TBR\(_{mean}\)) of lumbar vertebrae L2-L4 also correlated with bone marrow plasma cell (BMPC) infiltration in 11C-Methionine PET/CT (r = 0.789, p = 0.007) and 68Ga-Pentixafor PET/CT (r = 0.724, p = 0.018) PET/CT. In contrast, we did not observe a significant correlation between BMPC infiltration rate and TBR\(_{mean}\) in 18F-FDG PET/CT (r = 0.355, p = 0.313). Additionally, on 11C-Methionine PET/CT scans, we found a significant correlation between BMPC infiltration and TBR\(_{max}\) of lumbar vertebrae L2-L4 (r = 0.642, p = 0.045). In conclusion, 11C-Methionine and 68Ga-Pentixafor PET/CT demonstrate higher sensitivity than 18F-FDG PET/CT in detecting BM involvement in SMM.
Here, we assessed whether 36 single nucleotide polymorphisms (SNPs) within the TNFSF4 and MAPKAPK2 loci influence the risk of developing invasive aspergillosis (IA). We conducted a two-stage case control study including 911 high-risk patients diagnosed with hematological malignancies that were ascertained through the aspBIOmics consortium. The meta-analysis of the discovery and replication populations revealed that carriers of the TNFSF4\(_{rs7526628T/T}\) genotype had a significantly increased risk of developing IA (p = 0.00022). We also found that carriers of the TNFSF4\(_{rs7526628T}\) allele showed decreased serum levels of TNFSF14 protein (p = 0.0027), and that their macrophages had a decreased fungicidal activity (p = 0.048). In addition, we observed that each copy of the MAPKAPK2\(_{rs12137965G}\) allele increased the risk of IA by 60% (p = 0.0017), whereas each copy of the MAPKAPK2\(_{rs17013271T}\) allele was estimated to decrease the risk of developing the disease (p = 0.0029). Mechanistically, we found that carriers of the risk MAPKAPK2\(_{rs12137965G}\) allele showed increased numbers of CD38+IgM-IgD- plasmablasts in blood (p = 0.00086), whereas those harboring two copies of the allele had decreased serum concentrations of thymic stromal lymphopoietin (p = 0.00097). Finally, we also found that carriers of the protective MAPKAPK2\(_{rs17013271T}\) allele had decreased numbers of CD27-IgM-IgD- B cells (p = 0.00087) and significantly lower numbers of CD14+ and CD14+CD16- cells (p = 0.00018 and 0.00023). Altogether, these results suggest a role of the TNFSF4 and MAPKAPK2 genes in determining IA risk.
A new and easy polymerase chain reaction (PCR) multiplex strategy, for the identification of the most common fungal species involved in invasive fungal infections (IFI) was developed in this work. Two panels with species-specific markers were designed, the Candida Panel for the identification of Candida species, and the Filamentous Fungi Panel for the identification of Aspergillus species and Rhizopusarrhizus. The method allowed the correct identification of all targeted pathogens using extracted DNA or by colony PCR, showed no cross-reactivity with nontargeted species and allowed identification of different species in mixed infections. Sensitivity reached 10 to 1 pg of DNA and was suitable for clinical samples from sterile sites, with a sensitivity of 89% and specificity of 100%. Overall, the study showed that the new method is suitable for the identification of the ten most important fungal species involved in IFI, not only from positive blood cultures but also from clinical samples from sterile sites. The method provides a unique characteristic, of seeing the peak in the specific region of the panel with the correct fluorescence dye, that aids the ruling out of unspecific amplifications. Furthermore, the panels can be further customized, selecting markers for different species and/or resistance genes.
In the last decade there has been tremendous effort in offering better therapeutic management strategies to patients with hematologic malignancies. These efforts have ranged from biological to clinical approaches and resulted in the rapid development of new approaches. The main “problem” that comes with the high influx of newly approved drugs, which not only influences hematologists that frequently work with these drugs but also affects other healthcare professionals that work with hematologists in patient management, including intensive care unit (ICU) physicians, is they have to keep up within their specialty and, in addition, with the side-effects that can occur when encountering hematology-specific therapies. Nonetheless, there are few people that have an in-depth understanding of a specialty outside theirs. Thus, this manuscript offers an overview of the most common side-effects caused by therapies used in hematology nowadays, or that are currently being investigated in clinical trials, with the purpose to serve as an aid to other specialties. Nevertheless, because of the high amount of information on this subject, each chapter will offer an overview of the side-effects of a drug class with each reference of the section being intended as further reading.
\(^{11}\)C-methionine (\(^{11}\)C-MET) is a new positron emission tomography (PET) tracer for the assessment of disease activity in multiple myeloma (MM) patients, with preliminary data suggesting higher sensitivity and specificity than \(^{18}\)F-fluorodeoxyglucose (\(^{18}\)F-FDG). However, the value of tumor burden biomarkers has yet to be investigated. Our goals were to corroborate the superiority of \(^{11}\)C-MET for MM staging and to compare its suitability for the assessment of metabolic tumor burden biomarkers in comparison to \(^{18}\)F-FDG. Twenty-two patients with newly diagnosed, treatment-naïve symptomatic MM who had undergone \(^{11}\)C-MET and \(^{18}\)F-FDG PET/CT were evaluated. Standardized uptake values (SUV) were determined and compared with total metabolic tumor volume (TMTV) for both tracers: total lesion glycolysis (TLG) and total lesion \(^{11}\)C-MET uptake (TLMU). PET-derived values were compared to Revised International Staging System (R-ISS), cytogenetic, and serologic MM markers such as M component, beta 2 microglobulin (B2M), serum free light chains (FLC), albumin, and lactate dehydrogenase (LDH). In 11 patients (50%), \(^{11}\)C-MET detected more focal lesions (FL) than FDG (p < 0.01). SUVmax, SUVmean, SUVpeak, TMTV, and TLMU were also significantly higher in \(^{11}\)C-MET than in \(^{18}\)F-FDG (p < 0.05, respectively). \(^{11}\)C-MET PET biomarkers had a better correlation with tumor burden (bone marrow plasma cell infiltration, M component; p < 0.05 versus p = n.s. respectively). This pilot study suggests that \(^{11}\)C-MET PET/CT is a more sensitive marker for the assessment of myeloma tumor burden than \(^{18}\)F-FDG. Its implications for prognosis evaluation need further investigation.